Benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate
• 化学式: C₁₉H₂₀O₅
• 分子量: 328.4
• InChiKey: GVQLLDWWYDKCAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• IMMUNOPOTENTIATORY AGENTS
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0614357A1

  公开（公告）日：1994-09-14
• METHOD OF DNA VACCINATION
  申请人：GLAXO GROUP LIMITED

  公开号：EP1107785A1

  公开（公告）日：2001-06-20
• US7074770B1
  申请人：——

  公开号：US7074770B1

  公开（公告）日：2006-07-11
• [EN] IMMUNOPOTENTIATORY AGENTS<br/>[FR] AGENTS IMMUNOPOTENTIALISATEURS
  申请人：——

  公开号：WO1994007479A2

  公开（公告）日：1994-04-14

  [EN] This invention relates to the use of a class of compounds as immunopotentiators, compositions containing such compounds and their manufacture, combinations of such compounds with anti-tumour or anti-infective drugs and the use of such combinations in the prophylaxis or treatment of such diseases arising from tumours or infections.
  [FR] L'invention porte sur l'utilisation d'une classe de composés comme immunopotentialisateurs, des compositions contenant ces composés et leur fabrication, des combinaisons de ces composés avec ces médicaments antitumoraux et anti-infectieux ainsi que sur l'utilisation de ces combinaisons dans la prophylaxie ou le traitement de maladies d'origines tumorale ou infectieuse.
• [EN] METHOD OF DNA VACCINATION<br/>[FR] PROCEDE DE VACCINATION AU MOYEN D'ADN
  申请人：GLAXO GROUP LTD

  公开号：WO2000012121A1

  公开（公告）日：2000-03-09

  A method of vaccinating a mammal against a disease state, comprising administrating to said mammal, within an appropriate vector, a nucleotide sequence encoding an antigenic peptide associated with the disease state; additionally administering to said mammal a compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide, the compound being selected from the list contained herein, wherein the compound is preferably Tucaresol or a physiologically acceptable salt or ester thereof, where appropriate.